Skip to main content
Top
Published in: Rheumatology International 4/2013

01-04-2013 | Original Article

The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis

Authors: Vidya Limaye, Colin Luke, Graeme Tucker, Catherine Hill, Susan Lester, Peter Blumbergs, Peter Roberts-Thomson

Published in: Rheumatology International | Issue 4/2013

Login to get access

Abstract

The South Australian (SA) myositis database has registered all patients with biopsy-proven inflammatory myositis in SA from 1980 to 2009. We determined the incidence and associations of malignancy in myositis by linking this database with the SA cancer registry. Standardized incidence ratios (SIR) for malignancy were determined using the total SA population over the same time period, stratified by age and gender. The SIR for cancer in the myositis population (n = 373) was 1.39, p = 0.047. There was a trend towards an increased SIR in dermatomyositis but no increased risk of malignancy in polymyositis or inclusion body myositis. Malignancies of the lung and prostate were the commonest and 28 % of malignancies occurred within one year of IIM diagnosis. The odds of developing cancer were significantly raised in the presence of a shawl sign, male gender, and in patients with overlap syndrome or rheumatoid arthritis whilst myalgia was a significant protective factor. HLA-A28 allele was overrepresented in patients with malignancy (11 vs 2 %, p = 0.006). Patients in SA with myositis are at modestly increased risk for malignancy. We report clinical and genetic risk factors allowing the identification of patients at greatest risk for malignancy.
Literature
1.
go back to reference Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85(1):41–45PubMedCrossRef Stockton D, Doherty VR, Brewster DH (2001) Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 85(1):41–45PubMedCrossRef
2.
go back to reference Buchbinder R, Forbes A, Hall S et al (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med 134:1087–1095PubMed Buchbinder R, Forbes A, Hall S et al (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med 134:1087–1095PubMed
3.
go back to reference Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357:96–100PubMedCrossRef Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357:96–100PubMedCrossRef
4.
go back to reference Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6:9–13PubMedCrossRef Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6:9–13PubMedCrossRef
5.
go back to reference Dankó K, Ponyi A, Molnar AP, András C, Constantin T (2009) Paraneoplastic myopathy. Curr Opin Rheumatol 21(6):594–598PubMedCrossRef Dankó K, Ponyi A, Molnar AP, András C, Constantin T (2009) Paraneoplastic myopathy. Curr Opin Rheumatol 21(6):594–598PubMedCrossRef
6.
go back to reference Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E et al (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201(4):591–601PubMedCrossRef Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E et al (2005) Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 201(4):591–601PubMedCrossRef
7.
go back to reference Levine SM (2006) Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 18(6):620–624PubMedCrossRef Levine SM (2006) Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 18(6):620–624PubMedCrossRef
8.
go back to reference Peng JC, Sheen TS, Hsu MM (1995) Nasopharyngeal carcinoma with dermatomyositis: analysis of 12 cases. Arch Otolaryngol Head Neck Surg 121:1298–1301PubMedCrossRef Peng JC, Sheen TS, Hsu MM (1995) Nasopharyngeal carcinoma with dermatomyositis: analysis of 12 cases. Arch Otolaryngol Head Neck Surg 121:1298–1301PubMedCrossRef
9.
go back to reference Chan HL (1985) Dermatomyositis and cancer in Singapore. Int J Dermatol 24:447–450PubMed Chan HL (1985) Dermatomyositis and cancer in Singapore. Int J Dermatol 24:447–450PubMed
10.
go back to reference Chen YJ, Wu CY, Shen JL (2001) Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 144:825–831PubMedCrossRef Chen YJ, Wu CY, Shen JL (2001) Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 144:825–831PubMedCrossRef
11.
go back to reference Airo A, Pukkala E, Isomaki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population-based study. J Rheumatol 22:1300–1303 Airo A, Pukkala E, Isomaki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population-based study. J Rheumatol 22:1300–1303
12.
go back to reference Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326:363–367PubMedCrossRef Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326:363–367PubMedCrossRef
13.
go back to reference Bohan Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347CrossRef Bohan Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347CrossRef
14.
go back to reference Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH et al (1999) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70:360–374 Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH et al (1999) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70:360–374
15.
go back to reference Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84(4):231–249CrossRef Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senécal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84(4):231–249CrossRef
16.
go back to reference Targoff IN (1993) Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 100:116S–123SPubMedCrossRef Targoff IN (1993) Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol 100:116S–123SPubMedCrossRef
17.
go back to reference Ghirardello A, Zampieri S, Tarricone E, Iaccarino L, Bendo R, Briani C et al (2006) Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 39:217–221PubMedCrossRef Ghirardello A, Zampieri S, Tarricone E, Iaccarino L, Bendo R, Briani C et al (2006) Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 39:217–221PubMedCrossRef
18.
go back to reference Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9(4):R78PubMedCrossRef Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9(4):R78PubMedCrossRef
19.
go back to reference Gunawardena H, Betteridge ZE, McHugh NJ (2008) Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 20(6):675–680PubMedCrossRef Gunawardena H, Betteridge ZE, McHugh NJ (2008) Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 20(6):675–680PubMedCrossRef
20.
go back to reference Chinoy H, Fertig N, Oddis CV, Ollier WER, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66:1345–1349PubMedCrossRef Chinoy H, Fertig N, Oddis CV, Ollier WER, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66:1345–1349PubMedCrossRef
21.
22.
go back to reference Trallero-Araguás E, Labrador-Horrillo M, Selva-O’Callaghan A, Martínez MA, Martínez-Gómez X, Palou E et al (2010) Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 89(1):47–52CrossRef Trallero-Araguás E, Labrador-Horrillo M, Selva-O’Callaghan A, Martínez MA, Martínez-Gómez X, Palou E et al (2010) Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 89(1):47–52CrossRef
23.
go back to reference O’Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M et al (2006) Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 85(2):111–127CrossRef O’Hanlon TP, Carrick DM, Targoff IN, Arnett FC, Reveille JD, Carrington M et al (2006) Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 85(2):111–127CrossRef
24.
go back to reference Hohlfeld R (2002) Polymyositis and dermatomyositis. In: Karpati G (ed) Structural and molecular basis of skeletal muscle diseases. ISN Neuropath Press, Switzerland, pp 221–227 Hohlfeld R (2002) Polymyositis and dermatomyositis. In: Karpati G (ed) Structural and molecular basis of skeletal muscle diseases. ISN Neuropath Press, Switzerland, pp 221–227
25.
go back to reference Dalakas MC (2011) Pathophysiology of inflammatory and autoimmune myopathies. Presse Med 40:e237–e247PubMedCrossRef Dalakas MC (2011) Pathophysiology of inflammatory and autoimmune myopathies. Presse Med 40:e237–e247PubMedCrossRef
26.
go back to reference Chahin N, Engel AG (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70:418–424PubMedCrossRef Chahin N, Engel AG (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70:418–424PubMedCrossRef
27.
go back to reference Mastaglia FL, Philips VA (2002) Idiopathic inflammatory myopathies, epidemiology, classification and diagnostic criteria. Rheum Dis Clin North Am 28:723–741PubMedCrossRef Mastaglia FL, Philips VA (2002) Idiopathic inflammatory myopathies, epidemiology, classification and diagnostic criteria. Rheum Dis Clin North Am 28:723–741PubMedCrossRef
28.
go back to reference NE Breslow, NE Day Statistical methods in cancer research: vol II–The design and analysis of cohort studies. IARC Scientific Publications (International Agency for Research on Cancer), pp 49–51 NE Breslow, NE Day Statistical methods in cancer research: vol II–The design and analysis of cohort studies. IARC Scientific Publications (International Agency for Research on Cancer), pp 49–51
29.
go back to reference Limaye VS, Lester S, Bardy P, Thompson P, Cox S, Blumbergs P, Roberts-Thomson P (2012) A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis. Rheumatol Int 32(3):611–619 Limaye VS, Lester S, Bardy P, Thompson P, Cox S, Blumbergs P, Roberts-Thomson P (2012) A three-way interplay of DR4, autoantibodies and synovitis in biopsy-proven idiopathic inflammatory myositis. Rheumatol Int 32(3):611–619
30.
go back to reference Buchbinder R, Hill CL (2002) Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 4:415–426PubMedCrossRef Buchbinder R, Hill CL (2002) Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 4:415–426PubMedCrossRef
31.
go back to reference Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT (2010) Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 12:R70PubMedCrossRef Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT (2010) Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 12:R70PubMedCrossRef
32.
go back to reference Maoz CR, Langevitz P, Livneh A, Blumstein Z, Sadeh M, Bank I et al (1998) High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 27:319–324PubMedCrossRef Maoz CR, Langevitz P, Livneh A, Blumstein Z, Sadeh M, Bank I et al (1998) High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 27:319–324PubMedCrossRef
33.
go back to reference Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WFC (2009) Malignancy is associated with dermatomyositis but not polymyositis in Northern New England. USA J Rheumatol 36:2704–2710CrossRef Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WFC (2009) Malignancy is associated with dermatomyositis but not polymyositis in Northern New England. USA J Rheumatol 36:2704–2710CrossRef
34.
go back to reference Zhang W, Jiang SP, Huang L (2009) Dermatomyositis and malignancy: a retrospective study of 115 cases. Eur Rev Med Pharmacol Sci 13(2):77–80PubMed Zhang W, Jiang SP, Huang L (2009) Dermatomyositis and malignancy: a retrospective study of 115 cases. Eur Rev Med Pharmacol Sci 13(2):77–80PubMed
35.
go back to reference Lakhanpal S, Bunch TW, Ilstrup DM, Melton LJ 3rd (1986) Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 61:645–653PubMedCrossRef Lakhanpal S, Bunch TW, Ilstrup DM, Melton LJ 3rd (1986) Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 61:645–653PubMedCrossRef
36.
go back to reference Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P et al (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35:438–444PubMed Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P et al (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35:438–444PubMed
37.
go back to reference Barona P, Sierrasesumaga L, Antillon F, Villa-Elizaga I (1993) Study of HLA antigens in patients with osteosarcoma. Hum Hered 43(5):311–314PubMedCrossRef Barona P, Sierrasesumaga L, Antillon F, Villa-Elizaga I (1993) Study of HLA antigens in patients with osteosarcoma. Hum Hered 43(5):311–314PubMedCrossRef
38.
go back to reference Abrahamova J, Majsky A, Koutecky J (1981) HLA-antigens in germ cell tumours of various sites. Onkologie 4(1):19–20PubMedCrossRef Abrahamova J, Majsky A, Koutecky J (1981) HLA-antigens in germ cell tumours of various sites. Onkologie 4(1):19–20PubMedCrossRef
39.
go back to reference Hornmark-Stenstam B, Landberg T, Low B (1978) HLA antigens in Hodgkin’s disease of very long survival. Acta Radiol Oncol Radiat Phys Biol 17(4):283–288PubMedCrossRef Hornmark-Stenstam B, Landberg T, Low B (1978) HLA antigens in Hodgkin’s disease of very long survival. Acta Radiol Oncol Radiat Phys Biol 17(4):283–288PubMedCrossRef
40.
go back to reference Paul SM, Bacharach B, Goepp C (1987) A genetic influence on alveolar cell carcinoma. J Surg Oncol 36(4):249–252PubMedCrossRef Paul SM, Bacharach B, Goepp C (1987) A genetic influence on alveolar cell carcinoma. J Surg Oncol 36(4):249–252PubMedCrossRef
41.
go back to reference Illeni MT, Pasquali M, La Monica G, Bohm S, Rovini D, Di Re E (1985) HLA antigens in ovarian adenocarcinoma patients. Eur J Gynaecol Oncol 6(2):121–125PubMed Illeni MT, Pasquali M, La Monica G, Bohm S, Rovini D, Di Re E (1985) HLA antigens in ovarian adenocarcinoma patients. Eur J Gynaecol Oncol 6(2):121–125PubMed
42.
go back to reference Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA et al (2002) Southwest oncology group. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumour vaccine: impact of HLA Class I antigen expression on outcome. J Clin Oncol 20(8):2067–2075PubMedCrossRef Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA et al (2002) Southwest oncology group. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumour vaccine: impact of HLA Class I antigen expression on outcome. J Clin Oncol 20(8):2067–2075PubMedCrossRef
43.
go back to reference Luboldt HJ, Kubens BS, Rubben H, Grosse-Wilde H (1996) Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 56(4):826–830PubMed Luboldt HJ, Kubens BS, Rubben H, Grosse-Wilde H (1996) Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 56(4):826–830PubMed
Metadata
Title
The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis
Authors
Vidya Limaye
Colin Luke
Graeme Tucker
Catherine Hill
Susan Lester
Peter Blumbergs
Peter Roberts-Thomson
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2489-y

Other articles of this Issue 4/2013

Rheumatology International 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine